This clinical trial is focused on studying the treatment of Chronic Pulmonary Aspergillosis, a lung condition caused by a type of fungus called Aspergillus. The study aims to compare the effectiveness of two treatment approaches over a six-month period. One group of patients will receive a combination of two medications: itraconazole, which is taken orally, and AmBisome, which is inhaled. The other group will receive only itraconazole. The purpose of the study is to determine which treatment is more effective in improving the health of patients with this condition.
Participants in the study will be monitored for six months while receiving their assigned treatment. During this time, doctors will assess both clinical and radiological improvements, which means they will look for signs of better health and changes in lung images. After the treatment period, there will be a follow-up for 24 months to observe any long-term effects or relapses. The study will also evaluate the quality of life of participants using a questionnaire and track any major health events or hospital visits related to respiratory symptoms.
The study is designed for patients who are not severely immunocompromised, meaning their immune systems are not significantly weakened. It excludes those with a single aspergilloma, which is a specific type of fungal growth in the lungs. The trial is conducted in a single-blind manner, meaning that the patients do not know which treatment group they are in, but the researchers do. This helps ensure that the results are unbiased and reliable.
France 